Ildong Pharmaceutical Obtains Patent for New Diabetes Drug Substance in the US

Phase 1 Clinical Trial Underway in Germany
Simultaneous Commercialization and Technology Export Efforts Underway

[Asia Economy Reporter Kim Daehyun] Ildong Pharmaceutical has obtained a U.S. patent related to the new drug candidate for diabetes treatment, ‘IDG16177.’

On the 19th, Ildong Pharmaceutical (CEO Yoon Woongseop) announced that it had acquired a new substance patent for IDG16177 in the United States.

IDG16177 is a new drug candidate for type 2 diabetes in the GPR40 agonist class, which activates GPR40 (G protein-coupled receptor 40) in pancreatic beta cells to induce insulin secretion and regulate blood glucose levels.

IDG16177 is characterized by its ability to selectively induce insulin secretion during hyperglycemia, minimizing the risk of hypoglycemia side effects caused by administration. According to Ildong Pharmaceutical, animal experiments showed that it demonstrated superior blood glucose-lowering effects at doses 10 to 30 times lower than similar competitive substances, and also showed favorable results in safety evaluations related to toxicity.

Previously, Ildong Pharmaceutical obtained clinical trial approval (IND) for IDG16177 from the German Federal Institute for Drugs and Medical Devices (BfArM) last year. Currently, Phase 1 clinical trials are underway locally in Germany.

An Ildong Pharmaceutical official stated, "In addition to the United States, patents have already been registered in countries such as Korea, Japan, and Australia to secure favorable conditions and rights for commercialization, and patents for major markets such as Europe and China are also being filed." He added, "Along with conducting new drug development tasks such as efficacy verification and clinical data acquisition related to IDG16177, we plan to simultaneously pursue revenue realization strategies such as licensing out."

This content was produced with the assistance of AI translation services.